Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $7.60

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been assigned a consensus rating of “Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $7.60.

PRQR has been the subject of several recent analyst reports. Chardan Capital restated a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC raised its stake in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the period. Finally, Privium Fund Management B.V. raised its stake in shares of ProQR Therapeutics by 4.4% during the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after purchasing an additional 236,279 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Down 12.7 %

PRQR stock opened at $2.47 on Thursday. The business has a 50 day moving average price of $3.40 and a 200 day moving average price of $2.40. The stock has a market cap of $201.75 million, a price-to-earnings ratio of -8.13 and a beta of 0.24. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).